147 related articles for article (PubMed ID: 7527427)
1. Comparison of cord blood and peripheral blood mononuclear cells as targets for viral isolation and drug sensitivity studies involving human immunodeficiency virus type 1.
Salomon H; Belmonte A; Nguyen K; Gu Z; Gelfand M; Wainberg MA
J Clin Microbiol; 1994 Aug; 32(8):2000-2. PubMed ID: 7527427
[TBL] [Abstract][Full Text] [Related]
2. Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine.
Gu Z; Gao Q; Fang H; Salomon H; Parniak MA; Goldberg E; Cameron J; Wainberg MA
Antimicrob Agents Chemother; 1994 Feb; 38(2):275-81. PubMed ID: 7514855
[TBL] [Abstract][Full Text] [Related]
3. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.
Tisdale M; Kemp SD; Parry NR; Larder BA
Proc Natl Acad Sci U S A; 1993 Jun; 90(12):5653-6. PubMed ID: 7685907
[TBL] [Abstract][Full Text] [Related]
4. Bisheteroarylpiperazine reverse transcriptase inhibitor in combination with 3'-azido-3'-deoxythymidine or 2',3'-dideoxycytidine synergistically inhibits human immunodeficiency virus type 1 replication in vitro.
Chong KT; Pagano PJ; Hinshaw RR
Antimicrob Agents Chemother; 1994 Feb; 38(2):288-93. PubMed ID: 7514857
[TBL] [Abstract][Full Text] [Related]
5. Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine.
Schinazi RF; McMillan A; Cannon D; Mathis R; Lloyd RM; Peck A; Sommadossi JP; St Clair M; Wilson J; Furman PA
Antimicrob Agents Chemother; 1992 Nov; 36(11):2423-31. PubMed ID: 1283296
[TBL] [Abstract][Full Text] [Related]
6. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides.
Schinazi RF; Lloyd RM; Nguyen MH; Cannon DL; McMillan A; Ilksoy N; Chu CK; Liotta DC; Bazmi HZ; Mellors JW
Antimicrob Agents Chemother; 1993 Apr; 37(4):875-81. PubMed ID: 7684216
[TBL] [Abstract][Full Text] [Related]
7. High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase.
Boucher CA; Cammack N; Schipper P; Schuurman R; Rouse P; Wainberg MA; Cameron JM
Antimicrob Agents Chemother; 1993 Oct; 37(10):2231-4. PubMed ID: 7504909
[TBL] [Abstract][Full Text] [Related]
8. Genotypic and phenotypic characterization of HIV-1 isolated from patients receiving (--)-2',3'-dideoxy-3'-thiacytidine.
Kavlick MF; Shirasaka T; Kojima E; Pluda JM; Hui F; Yarchoan R; Mitsuya H
Antiviral Res; 1995 Oct; 28(2):133-46. PubMed ID: 8585767
[TBL] [Abstract][Full Text] [Related]
9. Activities of the four optical isomers of 2',3'-dideoxy-3'-thiacytidine (BCH-189) against human immunodeficiency virus type 1 in human lymphocytes.
Schinazi RF; Chu CK; Peck A; McMillan A; Mathis R; Cannon D; Jeong LS; Beach JW; Choi WB; Yeola S
Antimicrob Agents Chemother; 1992 Mar; 36(3):672-6. PubMed ID: 1320365
[TBL] [Abstract][Full Text] [Related]
10. Effects of 3'-deoxynucleoside 5'-triphosphate concentrations on chain termination by nucleoside analogs during human immunodeficiency virus type 1 reverse transcription of minus-strand strong-stop DNA.
Arts EJ; Marois JP; Gu Z; Le Grice SF; Wainberg MA
J Virol; 1996 Feb; 70(2):712-20. PubMed ID: 8551607
[TBL] [Abstract][Full Text] [Related]
11. Generation of drug-resistant variants of human immunodeficiency virus type 1 by in vitro passage in increasing concentrations of 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine.
Gao Q; Gu Z; Hiscott J; Dionne G; Wainberg MA
Antimicrob Agents Chemother; 1993 Jan; 37(1):130-3. PubMed ID: 8381634
[TBL] [Abstract][Full Text] [Related]
12. Effect of 3'-azido-3'-deoxythymidine on human immunodeficiency virus type 1 replication in human fetal brain macrophages.
Geleziunas R; Arts EJ; Boulerice F; Goldman H; Wainberg MA
Antimicrob Agents Chemother; 1993 Jun; 37(6):1305-12. PubMed ID: 8392310
[TBL] [Abstract][Full Text] [Related]
13. The K65R mutant reverse transcriptase of HIV-1 cross-resistant to 2', 3'-dideoxycytidine, 2',3'-dideoxy-3'-thiacytidine, and 2',3'-dideoxyinosine shows reduced sensitivity to specific dideoxynucleoside triphosphate inhibitors in vitro.
Gu Z; Fletcher RS; Arts EJ; Wainberg MA; Parniak MA
J Biol Chem; 1994 Nov; 269(45):28118-22. PubMed ID: 7525567
[TBL] [Abstract][Full Text] [Related]
14. Lamivudine or stavudine in two- and three-drug combinations against human immunodeficiency virus type 1 replication in vitro.
Merrill DP; Moonis M; Chou TC; Hirsch MS
J Infect Dis; 1996 Feb; 173(2):355-64. PubMed ID: 8568296
[TBL] [Abstract][Full Text] [Related]
15. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme.
Back NK; Nijhuis M; Keulen W; Boucher CA; Oude Essink BO; van Kuilenburg AB; van Gennip AH; Berkhout B
EMBO J; 1996 Aug; 15(15):4040-9. PubMed ID: 8670908
[TBL] [Abstract][Full Text] [Related]
16. Development of HIV-1 resistance to (-)2'-deoxy-3'-thiacytidine in patients with AIDS or advanced AIDS-related complex.
Wainberg MA; Salomon H; Gu Z; Montaner JS; Cooley TP; McCaffrey R; Ruedy J; Hirst HM; Cammack N; Cameron J
AIDS; 1995 Apr; 9(4):351-7. PubMed ID: 7540846
[TBL] [Abstract][Full Text] [Related]
17. Zidovudine-resistant human immunodeficiency virus type 1 genomes detected in plasma distinct from viral genomes in peripheral blood mononuclear cells.
Smith MS; Koerber KL; Pagano JS
J Infect Dis; 1993 Feb; 167(2):445-8. PubMed ID: 7678429
[TBL] [Abstract][Full Text] [Related]
18. (-)-2'-deoxy-3'-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro.
Coates JA; Cammack N; Jenkinson HJ; Jowett AJ; Jowett MI; Pearson BA; Penn CR; Rouse PL; Viner KC; Cameron JM
Antimicrob Agents Chemother; 1992 Apr; 36(4):733-9. PubMed ID: 1380229
[TBL] [Abstract][Full Text] [Related]
19. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy.
Larder BA; Kemp SD; Harrigan PR
Science; 1995 Aug; 269(5224):696-9. PubMed ID: 7542804
[TBL] [Abstract][Full Text] [Related]
20. The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine.
Gao Q; Gu Z; Parniak MA; Cameron J; Cammack N; Boucher C; Wainberg MA
Antimicrob Agents Chemother; 1993 Jun; 37(6):1390-2. PubMed ID: 8392313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
